ScholarIQanswers from OpenAlex

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

PaperCitations, authors & open-access status

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer have?

ScholarIQcitation count

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer has 119 citations in the OpenAlex counts ScholarIQ stores.

When was EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer published?

ScholarIQyear

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer has 2019 year in the ScholarIQ index.

What is the open-access status of EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer?

ScholarIQoa status

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer has gold oa status in the ScholarIQ index.

What is the DOI of EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer?

ScholarIQdoi

The DOI for EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer is on the source record.

What is the PMID of EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer?

ScholarIQpmid

The PMID for EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer is on the source record.

What is the OpenAlex record for EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer?

ScholarIQopenalex

The OpenAlex for EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial